Hallucinations during voriconazole therapy: Who is at higher risk and could benefit from therapeutic drug monitoring?

Therapeutic Drug Monitoring

Volumn 31, Issue 1, 2009, Pages 135-136

  Pea, Federico ^a   Viale, Pierluigi ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; OMEPRAZOLE; VORICONAZOLE;

AREA UNDER THE CURVE; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG POTENTIATION; HALLUCINATION; HUMAN; LETTER; NEUROTOXICITY; PHARMACOGENETICS; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; DRUG MONITORING; HALLUCINATIONS; HUMANS; NEUROTOXICITY SYNDROMES; PYRIMIDINES; RISK ASSESSMENT; TRIAZOLES;

EID: 60449091751     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181947901     Document Type: Letter

References (13)

1. Bruggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit. 2008;30: 403-411.
2. Zonios DI, Gea-Banacloche J, Childs R, et al. Hallucinations during voriconazole therapy. Clin Infect Dis. 2008;47:e7-e10.
3. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211.
4. Imhof A, Schaer DJ, Schanz U, et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006;136:739-742.
5. Meletiadis J, Chanock S, Walsh TJ. Human pharmacogenomic variations and their implications for antifungal efficacy. Clin Microbiol Rev. 2006; 19:763-787.
6. Geist MJ, Egerer G, Burhenne J, et al. Safety of voriconazole in a patient with CYP2C9*2/ CYP2C9*2 genotype. Antimicrob Agents Chemother. 2006;50:3227-3228.
7. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism, Clin Pharmacokinet. 2002;41:913-958.
8. Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs. 2008;68:925-947.
9. Foti RS, Wahlstrom JL. CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos. 2008;36:523-528.
10. Blume H, Donath F, Warnke A, et al. Pharma cokinetic drug interaction profiles of proton pump inhibitors. Drug Suf. 2006;29:769-784.
11. Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56(suppl):156-161.
12. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827.
13. Tanaka T, Moretti ME, Verjee ZH, Shupak M, Ivanyi KE, Ito S. A Pitfall of Measuring Lithium Levels in Neonates. Ther Drug Monit 2008;30:752-754.